CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Alimtadrug
Likely dose
Alimta 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00508144
NCT00508144Phase 2Completed
CompareCT.gov

Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center·interventional·Posted Jul 27, 2007·Updated Feb 13, 2017

In Brief

A Phase 2 clinical trial evaluating Alimta for Lung Cancer. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn how effective the drug pemetrexed (ALIMTA®) is in treating advanced NSCLC in patients with poor performance status (PS) (inability to perform every day activities without difficulty). Objectives: Primary Objectives: * PS = 2 cohort: Response * PS = 3 cohort: Descriptive Secondary Objectives: * Tolerability of single agent pemetrexed (Alimta®) in PS = 3 NSCLC patients * Improved symptoms (both cohorts) * Molecular Correlative studies (both cohorts) * Overall survival * Time to progression

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 27, 2007
Enrollment StartSep 1, 2005
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10.3 yearsPosted 18.9 years ago

Interventions

Alimtadrug

500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks